Literature DB >> 21130194

Optimal vaccination strategies for 2009 pandemic H1N1 and seasonal influenza vaccines in humans.

Jiang Wu1, Xiang Zhong, Chris Ka-fai Li, Jian-fang Zhou, Min Lu, Kuan-Ying Huang, Mei Dong, Yan Liu, Feng-Ji Luo, Ning Du, Cecilia Chui, Li-Qi Liu, Nicola M G Smith, Bo Li, Nian-Min Shi, Li-Fei Song, Yan Gao, Da-Yan Wang, Xu Wang, Wen-Fei Zhu, Yan Yan, Zi Li, Jiang-Ting Chen, Andrew J McMichael, Wei-Dong Yin, Xiao-Ning Xu, Yuelong Shu.   

Abstract

A randomized clinical trial was conducted to assess whether the immunogenicity of seasonal and pandemic (H1N1/09) influenza vaccines is affected by the order of vaccine administration. 151 healthy adult volunteers were randomized into three groups. All groups received one dose (15 μg haemagglutinin) each of a pandemic H1N1 vaccine and a seasonal trivalent vaccine. Group 1 received the pandemic H1N1 vaccine first, followed by the seasonal vaccine 21 days later. Group 2 received vaccinations in vice versa and Group 3 received both vaccines simultaneously. Post-vaccination blood samples were collected to determine the immunogenicity by hemagglutination-inhibition (HI), microneutralization (MN), and B cell ELISPOT assays. All three vaccination strategies were well-tolerated and generated specific immune responses. However, we found a significant difference in magnitude of antibody responses to pandemic H1N1 between the three groups. Pre- or co-vaccination with the seasonal flu vaccine led to a significant reduction by 50% in HI titre to pandemic H1N1 virus after pandemic vaccination. Pre- or co-vaccination of pandemic H1N1 vaccine had no effect on seasonal flu vaccination. MN and ELISPOT assays showed a similar effect. Vaccination with pandemic H1N1 vaccine first is recommended to avoid an associated inhibitory effect by the seasonal trivalent flu vaccine. Crown Copyright Â
© 2010. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21130194     DOI: 10.1016/j.vaccine.2010.11.058

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Epidemic and intervention modelling--a scientific rationale for policy decisions? Lessons from the 2009 influenza pandemic.

Authors:  Maria D Van Kerkhove; Neil M Ferguson
Journal:  Bull World Health Organ       Date:  2012-04-01       Impact factor: 9.408

Review 2.  Review of 10 years of clinical experience with Chinese domestic trivalent influenza vaccine Anflu®.

Authors:  Yan Liu; Jun-Yu Wu; Xu Wang; Jiang-Ting Chen; Ming Xia; Wei Hu; Yong Zou; Wei-Dong Yin
Journal:  Hum Vaccin Immunother       Date:  2013-10-08       Impact factor: 3.452

3.  Focused antibody response to influenza linked to antigenic drift.

Authors:  Kuan-Ying A Huang; Pramila Rijal; Lisa Schimanski; Timothy J Powell; Tzou-Yien Lin; John W McCauley; Rodney S Daniels; Alain R Townsend
Journal:  J Clin Invest       Date:  2015-05-26       Impact factor: 14.808

4.  Seroprevalence of pandemic H1N1 antibody among health care workers in Hong Kong following receipt of monovalent 2009 H1N1 influenza vaccine.

Authors:  Ying Zhou; Diane M W Ng; Wing-Hong Seto; Dennis K M Ip; Henry K H Kwok; Edward S K Ma; Sophia Ng; Lincoln L H Lau; J S Malik Peiris; Benjamin J Cowling
Journal:  PLoS One       Date:  2011-11-10       Impact factor: 3.240

Review 5.  B Cells and Functional Antibody Responses to Combat Influenza.

Authors:  Giuseppe Lofano; Arun Kumar; Oretta Finco; Giuseppe Del Giudice; Sylvie Bertholet
Journal:  Front Immunol       Date:  2015-06-30       Impact factor: 7.561

6.  Hemagglutinin stem reactive antibody response in individuals immunized with a seasonal influenza trivalent vaccine.

Authors:  Xiaopeng Zhao; Kun Qin; Jinlei Guo; Donghong Wang; Zi Li; Wenfei Zhu; Liqi Liu; Dayan Wang; Yuelong Shu; Jianfang Zhou
Journal:  Protein Cell       Date:  2015-06       Impact factor: 14.870

7.  Responses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: a randomized, observer-blind, controlled study.

Authors:  Sumita Roy-Ghanta; Robbert Van der Most; Ping Li; David W Vaughn
Journal:  J Infect Dis       Date:  2014-05-26       Impact factor: 5.226

8.  Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.

Authors:  Robbert G van der Most; Frédéric Clément; Julie Willekens; Walthère Dewé; Karl Walravens; David W Vaughn; Geert Leroux-Roels
Journal:  Clin Vaccine Immunol       Date:  2017-06-05

9.  Multi-centre observational study of transplacental transmission of influenza antibodies following vaccination with AS03(A)-adjuvanted H1N1 2009 vaccine.

Authors:  Richard Puleston; George Bugg; Katja Hoschler; Justin Konje; James Thornton; Iain Stephenson; Puja Myles; Joanne Enstone; Glenda Augustine; Yvette Davis; Maria Zambon; Karl Nicholson; Jonathan Nguyen-Van-Tam
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

Review 10.  A review of the evidence to support influenza vaccine introduction in countries and areas of WHO's Western Pacific Region.

Authors:  Gina Samaan; Michelle McPherson; Jeffrey Partridge
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.